|
Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers. |
|
|
Employment - Genome Insight |
Leadership - Genome Insight |
|
|
Employment - Genome Insight |
Leadership - Genome Insight |
|
|
Employment - Genome Insight |
Leadership - Genome Insight |
|
|
Employment - Genome Insight |
Leadership - Genome Insight |
|
|
Employment - Genome Insight |
Leadership - Genome Insight |
|
|
Employment - Genome Insight |
Leadership - Genome Insight |
Travel, Accommodations, Expenses - Genome Insight |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Lilly; Merck; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca; Gencurix (Inst); Genome Insight (Inst); NGeneBio (Inst); Pfizer; Roche (Inst) |
|
|
Employment - Genome Insight |
Stock and Other Ownership Interests - Genome Insight |